Respiratory Research · 2021 · 23 citations · 17 references
MedicineClinical SciencesInternal MedicineClinical EpidemiologyPulmonary Function TestingPulmonologyChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease PharmacotherapyObstructive Lung DiseasePulmonary Function AssessmentPulmonary InflammationRespiratory DiseaseChronic Obstructive Pulmonary Disease Exacerbation TreatmentChronic Obstructive Pulmonary Disease PathophysiologyExacerbation Severity AssessmentFibrinogen BindingFibrinogen InfluencePredictive Biomarker AssessmentPredictive Biomarker DevelopmentPulmonary Exacerbations
BACKGROUND: Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients with symptomatic COPD at risk of exacerbations. This analysis used IMPACT trial data to examine the relationship between fibrinogen levels and exacerbation outcomes in patients with COPD. METHODS: 8094 patients with a fibrinogen assessment at Week 16 were included, baseline fibrinogen data were not measured. Post hoc analyses were performed by fibrinogen quartiles and by 3.5 g/L threshold. Endpoints included on-treatment exacerbations and adverse events of special interest (AESIs). RESULTS: Rates of moderate, moderate/severe, and severe exacerbations were higher in the highest versus lowest fibrinogen quartile (0.75, 0.92 and 0.15 vs 0.67, 0.79 and 0.10, respectively). The rate ratios (95% confidence interval [CI]) for exacerbations in patients with fibrinogen levels ≥ 3.5 g/L versus those with fibrinogen levels < 3.5 g/L were 1.03 (0.95, 1.11) for moderate exacerbations, 1.08 (1.00, 1.15) for moderate/severe exacerbations, and 1.30 (1.10, 1.54) for severe exacerbations. There was an increased risk of moderate/severe exacerbation (hazard ratio [95% CI]: highest vs lowest quartile 1.16 [1.04, 1.228]; ≥ 3.5 g/L vs < 3.5 g/L: 1.09 [1.00, 1.16]) and severe exacerbation (1.35 [1.09, 1.69]; 1.27 [1.08, 1.47], respectively) with increasing fibrinogen level. Cardiovascular AESIs were highest in patients in the highest fibrinogen quartile. CONCLUSIONS: Rate and risk of exacerbations was higher in patients with higher fibrinogen levels. This supports the validity of fibrinogen as a predictive biomarker for COPD exacerbations, and highlights the potential use of fibrinogen as an enrichment strategy in trials examining exacerbation outcomes. TRIAL REGISTRATION: NCT02164513.
17
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
David A. Lipson, Frank Barnhart, Noushin Brealey et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text
Changes in Forced Expiratory Volume in 1 Second over Time in COPD
Jørgen Vestbo, Lisa Edwards, Paul D. Scanlon et al. · New England Journal of Medicine · 2011 · 958 citations · Full text
Peter A. McCullough, Judd E. Hollander, Richard M. Nowak et al. · Academic Emergency Medicine · 2003 · 203 citations